|
1. A method of reducing or preventing neurological deficit and/or neuronal cell death in a human subject, said subject having had a prior neuronal transient ischemic attack (NTIA) wherein said neurological deficit and/or neuronal cell death reduction or prevention is relative to that level occurring in the absence of addressing such potential deficit or death, the instant method comprising orally administering glyceryl tris (beta-hydroxybutyrate) (GTβHB) to said subject on a daily basis in a daily amount calculated to result in a combined beta-hydroxybutyrate moiety and acetoacetate blood plasma concentration of 2 mM to 7 mM in 1-4 fractional servings per day for an administration period having a range selected from the group of ranges having a minimum and a maximum independently selected from the group consisting of 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days 13 days, 14 days, 15 days, 16 days, 17 days 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26, days, 27 days, 28 days, 29 days, 30 days, 31 days, 35 days, 42 days, 49 days, 56 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 70 days, 77 days, 84 days, 90 days, 91 days, 92 days, 98 days, 105 days, 112 days, 119 days, 120 days, 126 days, 133 days, 140 days, 5 months, 6 months, 7 months, 8 months, 9 months, and 1 year proved said minimum is less than said maximum, said administration period counting the days from said previous NTIA, where said previous NTIA date is counted as day zero, optionally interrupted by one or more days, and wherein the occurrence of a follow-on NTIA resets the day count to day zero on the day of the follow-on NTIA.
|